The lectin-like oxidized low-density lipoprotein receptor-1 as therapeutic target for atherosclerosis, inflammatory conditions and longevity

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 8, 2013, Pages 905-919

  Ulrich Merzenich, Gudrun ^a   Zeitler, Heike ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Atherosclerosis; Cardiovascular diseases; Imipramine; Inflammation; LOX 1 antibodies; LOX 1 receptor; Omics; Salicyclic acid

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; BERBERINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; COMPLEMENTARY RNA; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; JTX 92; LIPOPROTEIN; MICRORNA; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1 ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROCYANIDIN; PYRROLE IMIDAZOLE POLYAMIDE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TANSHINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; CHINESE HERB; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; GENOMICS; HUMAN; INFLAMMATION; LONGEVITY; MAXIMUM PLASMA CONCENTRATION; MEDICINAL PLANT; MOLECULAR BIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION; WILLOW;

ANIMALS; ANTIBODIES; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; LONGEVITY; MICRORNAS; RNA, ANTISENSE; SCAVENGER RECEPTORS, CLASS E;

EID: 84880359674     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.805748     Document Type: Review

References (110)

1. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7 (Pubitemid 27130922)
2. Yoshimoto R, Fujita Y, Kakino A, et al. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 2011;25:379-91
3. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002;17:353-62 (Pubitemid 35279555)
4. Matushansky I, Hernando E, Socci ND, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008;172:1069-80 (Pubitemid 351520003)
5. Halvorsen B, Staff AC, Henriksen T, et al. 8-iso-prostaglandin F(2a) increases expression of LOX-1 in JAR cells. Hypertension 2001;37:1184-90 (Pubitemid 32304023)
6. Ishikawa M, Ito H, Akiyoshi M, et al. Lectin-like oxidized low-density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis. Arthritis Rheum 2012;64:1024-34
7. Zhang D, Sun L, Zhu H, et al. Microglial LOX-1 reacts with extracellular HSP60 to bridge neuroinflammation and neurotoxicity. Neurochem Int 2012;61:1021-35
8. Kume N, Kita T. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr Opin Lipidol 2001;12:419-23 (Pubitemid 32675503)
9. Sawamura T, Kakino A, Fujita Y. LOX-1: a multiligand receptor at the crossroads of response to danger signals. Curr Opin Lipidol 2012;23:439-45
10. Balin M, Celik A, Kobat MA, Baydas A. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI. J Thromb Thrombolysis 2012;34:483-90
11. Balin M, Celik A, Kobat MA. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are associated with proximal middle segment of the LAD lesions in patients with stable coronary artery disease. Clin Res Cardiol 2012;101:247-53
12. Samson S, Mundkur L, Kakkar VV. Immune Response to Lipoproteins in Atherosclerosis Cholesterol. 2012;2012:571846
13. WHO. Cardiovascular diseases (CVDs). 2009. Available from: www.who.int/mediacentre/factsheets/fs317/en/index. html
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
15. Ross R. The pathogenesis of atherosclerosis : a perspective for the 1990s. Nature 1993;362:801-9
16. Steinberg D. The LDL modification hypothesis of atherogenesis : an update. J Lipid Res 2009;50(Suppl):S376-81
17. Tabas I, Williams K, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation. 2007;116:1832-44 (Pubitemid 350287108)
18. Twigg MW, Freestone K, Homer-Vanniasinkam S, Ponnambalam S. The LOX-1 scavenger receptor and its implications in the treatment of vascular disease. Cardiol Res Pract 2012;2012:632408
19. Goyal T, Mitra S, Khaidakov M, et al. Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep 2012;14:150-9
20. Kataoka H, Kume N, Miyamoto S, et al. Expression of lectin like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999;99:3110-17 (Pubitemid 29289075)
21. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL [LOX-1] by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000;20:1116-22 (Pubitemid 30207591)
22. Li D, Liu L, Chen H, et al. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-17 (Pubitemid 36176813)
23. Hu C, Dandapat A, Sun L, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knockout mouse cardiac fibroblasts. J Biol Chem 2008;283:10226-31
24. Mehta JL, Sanada N, Hu CP, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007;100:1634-42 (Pubitemid 46897266)
25. Zhu H, Xia M, Hou M, et al. Ox-LDL plays a dual effect in modulating expression of inflammatory molecules through LOX-1 pathway in human umbilical vein endothelial cells. Front Biosci 2005;10:2585-94 (Pubitemid 40905262)
26. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4
27. Ryoo S, Bhunia A, Chang F, et al. OxLDL-dependent activation of Arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis 2011;214:279-87
28. Morawietz H. LOX-1 and atherosclerosis: proof of concept in LOX-1-knockout mice. Circ Res 2007;100:1534-6 (Pubitemid 46897254)
29. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000;101:2889-95 (Pubitemid 30415877)
30. Sugimoto K, Ishibashi T, Sawamura T, et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res 2009;84:127-36
31. Inoue K, Arai Y, Kurihara H, et al. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 2005;97:176-84 (Pubitemid 41033474)
32. Hu C, Dandapat A, Sun L, et al. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res 2008;79:287-93 (Pubitemid 351951615)
33. Eichhorn B, Muller G, Leuner A, et al. Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet. Cardiovasc Res 2009;82:493-502
34. White SJ, Sala-Newby GB, Newby AC. Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(-/-) mouse model.Cardiovasc Pathol. 2009;20:369-73
35. Biocca S, Filesi I, Mango R, et al. The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. J Mol Cell Cardiol 2008;44:561-70
36. Mango R, Biocca S, del Vecchio F, et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res 2005;97:152-8 (Pubitemid 41033471)
37. Chui PC, Guan HP, Lehrke M, Lazar MA. PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor. J Clin Invest 2005;115:2244-56. (Pubitemid 41134167)
38. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002;95:89-100
39. Tanigawa H, Miura S, Zhang B, et al. Low-density lipoprotein oxidized to various degrees activates ERK1/2 through Lox-1. Atherosclerosis 2006;188:245-50 (Pubitemid 44301131)
40. Apostolov EO, Shah SV, Ray D, Basnakian AG. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009;29:1622-30
41. Lu J, Yang JH, Burns AR, et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009;104:619-27
42. Murshid A, Theriault J, Gong J, Calderwood SK. Investigating receptors for extracellular heat shock proteins. Methods Mol Biol 2011;787:289-302
43. Feige JN, Gelman L, Rossi D, et al. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor-modulator that promotes adipogenesis. J Biol Chem 2007;282:19152-66 (Pubitemid 47100190)
44. Lee KA, Hammerle LP, Andrews PS, et al. Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels. J Biol Chem 2011;286:41530-8
45. Theriault JR, Mambula SS, Sawamura T, et al. Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett 2005;579:1951-60 (Pubitemid 40404037)
46. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL and eNOS-activating pathways in patients with coronary artery diseases. J Clin Invest 2011;121:2693-708
47. Shimaoka T, Kume N, Minami M, et al. LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol 2001;166:5108-14 (Pubitemid 32280724)
48. Campbell LA, Puolakkainen M, Lee A, et al. Chlamydia pneumonia binds to the lectin-like oxidized LDL receptor for infections of endothelial cells. Microbes Infect 2012;14:43-9
49. Yoshida T, Koide N, Mori H, et al. Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells. FEMS Microbiol Lett 2006;260:17-22 (Pubitemid 43873567)
50. Xie J, Zhu H, Guo L, et al. Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein 60-fused antigen into the MHC class I presentation pathway. J Immunol 2010;185:2306-13
51. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation 2003;108:1917-23 (Pubitemid 37296533)
52. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006;113:2135-50; discussion 2151
53. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasmamembrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-56
54. Murphy JE, Tacon D, Tedbury PR, et al. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J 2006;393(Pt1):107-15 (Pubitemid 43049307)
55. Honjo M, Nakamura K, Yamashiro K, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA 2003;100:1274-9 (Pubitemid 36183992)
56. Sakamoto N, Ishibashi T, Sugimoto K, et al. Role of LOX-1 in monocyte adhesion-triggered redox, Akt/eNOS and Ca2+ signaling pathways in endothelial cells. J Cell Physiol 2009;220:706-15
57. Mango R, Clementi F, Borgiani P, et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 2003;40:933-6 (Pubitemid 38117545)
58. Tatsuguchi M, Furutani M, Hinagata J, et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003;303:247-50 (Pubitemid 36338232)
59. Biocca S, Falconi M, Filesi I, et al. Functional analysis and molecular dynamics simulation of LOX-1 K167N polymorphism reveal alteration of receptor activity. PLoS One 2009;4:e4648
60. Predazzi IM, Norata GD, Vecchione L, et al. Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. PLoS One 2012;7:e31086
61. Matsunaga S, Xie Q, Kumano M, et al. Lectin-like oxidized low-density lipoprotein receptor (LOX-1) functions as an oligomer and oligomerization is dependent on receptor density. Exp Cell Res 2007;313:1203-14 (Pubitemid 46427821)
62. Xie Q, Matsunaga S, Niimi S, et al. Human lectin-like oxidized low-density lipoprotein receptor-1 functions as a dimer in living cells. DNA Cell Biol 2004;23:111-17 (Pubitemid 38221928)
63. Ishigaki T, Ohki I, Oyama T, et al. Purification, cristallization and prelimanary X-ray analysis of the ligand binding domain of human like oxidized low-density lipoprotein receptor 1 (LOX-1). Acta Crystallogr Sect F Struct Biol Cryst Commun 2005;61(Pt 5):524-7 (Pubitemid 44210879)
64. Ohki J, Ishigaki T, Oyama T, et al. Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to oxLDL. Structure 2005;13:905-17 (Pubitemid 40804393)
65. Murase T, Kume N, Kataoka H, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 2000;20:715-20 (Pubitemid 30151686)
66. Hayashida K, Kume N, Murase T, et al. Serum soluble lectin-like oxidized low density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005;112:812-18 (Pubitemid 41170066)
67. Kume N, Mitsuoka H, Hayashida K, et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome-Comparison with other biomarkers. J Cardiol 2010;56:159-65
68. Kume N, Mitsuoka H, Hayashida K, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome-a pilot study. Circ J 2010;74:1399-404
69. Zhao ZW, Zhu XL, Luo YK, et al. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are associated with angiographic coronary lesions complexity in patients with coronary artery disease. Clin Cardiol 2011;34:172-7
70. Kamezaki F, Yamashita K, Tasaki H, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 correlates with oxidative stress markers in stable coronary artery disease. Int J Cardiol 2009;134:285-7
71. Mehta JL, Li DY. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 1998;248:511-14 (Pubitemid 28404451)
72. Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999;100:899-902 (Pubitemid 29407168)
73. Morawietz H. LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis. Dtsch Med Wochenschr 2010;135:308-12
74. Khaidakov M, Mitra S, Kang BY, et al. Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, hyperlipidemia and cancer. PLoS One 2011;6:e20277
75. Saito A, Shimizu H, Doi Y, et al. Immunoliposomal drug-delivery system targeting lectin-like oxidized low-density lipoprotein receptor-1 for carotid plaque lesions in rats. J Neurosurg 2011;115:720-7
76. Kobayashi N, Yoshida K, Mita S, et al. Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. J Hypertens 2004;22:1397-402 (Pubitemid 38888087)
77. Kita T. LOX-1, a possible clue to the missing link between hypertension and atherogenesis. Circ Res 1999;84:1113-15 (Pubitemid 29227691)
78. Metha JL, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003;23:2203-8 (Pubitemid 37532321)
79. Ulrich-Merzenich G, Kelber O, Koptina A, et al. Novel neurological and immunological targets for salicylate-based phytopharmaceuticals and for the anti-depressant imipramine. Phytomedicine 2012;19:930-9
80. Mehta JL, Chen J, Yu F, Li DY. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovas Res 2004;64:243-9 (Pubitemid 39361685)
81. Marwali MR, Hu CP, Mohandas B, et al. Modulation of ADP-Induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharm Exp Ther 2007;322:1324-32 (Pubitemid 47295783)
82. Chen JW, Zhou SB, Tan ZM. Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells. Chin Med J 2010;123:1553-60
83. Vrontaki E, Leonis G, Papadopoulos MG, et al. Comparative binding effects of aspirin and anti-inflammatory Cu complex in the active site of LOX-1. J Chem Inf Model 2012;52:3293-301
84. Xu S, Liu Z, Huang Y, et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kB activation. Transl Res 2012;160:114-24
85. Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech 2010;11(2):582-7
86. Huang Z, Dong F, Li S, et al. Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 2012;690:164-9
87. Zeng X, Zeng X. Relationship between the clinical effect of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC. Biomed Chromatogr 1999;13:442-4 (Pubitemid 29533134)
88. Zhu JX, Tang D, Feng L, et al. Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride. Drug Dev Ind Pharm 2013;39:499-506
89. Kang Q, Chen A. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like LDL receptor. Lab Invest 2009;89:1275-90.
90. Kang BY, Khan JA, Ryu S, et al. Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol 2010;55:417-24
91. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of Curcumin: problems and Promises. Mol Pharm 2007;4:807-18
92. Zhu X, Li Z, Li C, et al. Ginkgo biloba extract and Aspirin synergistically attenuate activated platelet-induced ROS production and LOX-1 expression in human coronary artery endothelial cells. Phytomedicine 2013;20:114-19
93. Chang HC, Chen TG, Tai YT, et al. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J Cereb Blood Flow Metab 2011;31:842-54
94. Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32:1377-82 (Pubitemid 39564557)
95. Yamagata K, Miyashita A, Chino M, Matsufuji H. Apigenin inhibits tumor necrosis factor alpha plus high glucose-induced LOX-1 expression in human endothelial cells. Microvasc Res 2011;81:60-7
96. Ninfali P, Dominici S, Angelino D, et al. An enzyme-linked immunosorbent assay for the measurement of plasma flavonoids in Apigenin-C-Glycoside fed mice. J Sci Food Agric 2013; Epub ahead of print
97. Nahrstedt A, Schmidt M, Jäggi R, et al. Willow bark extract : the contribution of polyphenols to the overall effect. Wien Med Wochenschr 2007;157:348-51 (Pubitemid 47356262)
98. Nishizuka T, Fujita Y, Sato Y, et al. Procyanidins are potent inhibitors of LOX-1: a new player in the French Paradox. Proc Jpn Acad Ser B Phys Biol Sci 2011;87:104-13
99. Cao W, Calabro V, Root A, et al. Oligomerization is required for the activity of recombinant soluble LOX-1. FEBS J 2009;276:4909-20
100. Chen KC, Hsieh IC, His E, et al. Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1. J Cell Sci 2011;124:4115-24
101. Ding Z, Wang X, Khaidakov M, et al. MicroRNA hsa-let-7g targets lectin-like oxidized low-density lipoprotein receptor-1 expression and inhibits apoptosis in human smooth muscle cells. Exp Biol Med (Maywood) 2012;237:1093-100
102. Qin B, Xiao B, Jiang T, Yang H. Effects of miR-590-5p on ox-LDL-induced endothelial cells apoptosis and LOX-1 expression. J Cent South Univ (Med Sci) 2012;37:675-81; Chinese
103. Fujita Y, Kakino A, Nishimichi N, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-94
104. Melander C, Burnett R, Gottesfeld JM. Regulation of gene expression with pyrrole-imidazole polyamides. J Biotechnol 2004;112:195-220 (Pubitemid 39037399)
105. Ueno T, Fukuda N, Tsunemi A, et al. A novel gene silencer, pyrrole-imidazole polyamide targeting human lectin-like oxidized low-density lipoprotein receptor-1 gene improves endothelial cell function. J Hypertens 2009;27(3):508-16
106. Yao EH, Fukuda N, Ueno T, et al. Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury. Hypertension 2008;52:86-92
107. Amati F, Diano L, Vecchione L, et al. LOX-1 inhibition in ApoE KO mice using a Schizophyllan-based Antisense Oligonucleotide Therapy. Mol Ther Nucleic Acids 2012;1:e58
108. Morawietz H, Goettsch W, Brux M, et al. Lipoprotein apharesis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. Atheroscler Suppl 2013;14:107-13
109. Ulrich-Merzenich G, Panek D, Zeitler H, et al. Drug development from natural products exploiting synergy effects. Ind J Exp Biol 2010;48:208-19
110. Winnik S, Stein S, Matter CM. SIRT-1 an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Phamacol 2012;10:693-6